Evidence map›Paper›PMID 30090206›Full record

ArticleAvicenna journal of medical biotechnology

Soluble Expression of Humanized Anti-CD20 Single Chain Antibody in

Mohammadreza Yousefi, Safar Farajnia, Ahad Mokhtarzadeh, Bahman Akbari, Shiva Ahdi Khosroshahi, Mina Mamipour, Hassan Dariushnejad, Vahideh Ahmadzadeh

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Evolution ofInternational journal of molecular sciences · 2020
    Review
  5. Optimization ofAvicenna journal of medical biotechnology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Mohammadreza YousefiDepartment of Biotechnology, Higher Education Institute of Rab-Rashid, Tabriz, Iran.
Safar FarajniaDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ahad MokhtarzadehDepartment of Biotechnology, Higher Education Institute of Rab-Rashid, Tabriz, Iran.
Bahman AkbariDepartment of Medical Biotechnology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Shiva Ahdi KhosroshahiBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mina MamipourDepartment of Biotechnology, Higher Education Institute of Rab-Rashid, Tabriz, Iran.
Hassan DariushnejadImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Vahideh AhmadzadehBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IRBiotechnology Research Center · IRGonabad University of Medical Sciences · IRKermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCD20 is an important cell surface receptor that is used for target therapy of B cell lymphoma and some related blood diseases due to vital function of CD20. In previous studies, a Rituximab based humanized single chain variable fragment (scFv) antibody showed good reactivity against B cell related cancer cells. But this recombinant protein produced Inclusion Bodies (IBs) in

methodsFor this purpose, the fragment coding for anti-CD20 huscFv subcloned into the pET22b (+) and transformed into the

resultCoexpression with cytoplasmic chaperones led to increased soluble expression of anti-CD20 recombinant protein. Among investigated chaperones, pKJE7 chaperone plasmid containing DnaJ, GrpE, DnaK chaperone genes had significant effects with an expression yield of 325

conclusionThe result of this study demonstrated remarkable effect of pKJE7 chaperone on enhancement of soluble expression of anti-CD20 huscFv antibody in

Indexed as

Molecular chaperonesNon Hodgkin lymphomaSingle chain antibody

Identifiers

PMID30090206
PMCPMC6063999
OpenAlexW2884362210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.